Search results: (10000)
News Recommendations for Lipid Administration in Patients on Home Parenteral Therapy
Home parenteral therapy is an important part of treatment for patients with chronic intestinal failure who cannot achieve adequate nutrition through enteral feeding. An integral component of this therapy is lipid emulsion, which provides a source of energy and essential fatty acids. However, long-term administration of lipid emulsion may be associated with liver damage. According to available studies, the risk can be reduced by adjusting the dosage of lipid emulsion and preferring emulsions without soybean oil.
News Dosing and Consumption of rFVIII Products with Extended Half-life in Patients with Hemophilia A in Real-World Practice
Based on real-world data from the USA, a recently published study compared two recombinant human factor VIII (rFVIII) products with extended half-life (EHL) – efmoroctocog alfa and rurioctocog alfa pegol, in terms of dosing frequency, weekly consumption, and dose variability.
News Quick Relief from Severe AD Symptoms – Dupilumab for Children Aged 6 Years and Older
Children aged 6-12 with severe atopic dermatitis (AD) have very limited treatment options. The studies presented below demonstrate how effective and safe dupilumab, a monoclonal antibody targeting interleukins 4 and 13, is in their case. Since October, this medication is newly covered even for children from 6 years of age.
News Stable Position of Micronized Diosmin in the Treatment of Chronic Venous Insufficiency and Hemorrhoids
Diosmin is a flavonoid used in Europe as a venotonic and vasoprotective agent for over 40 years. Significant progress has been made in medicine during this time, yet the role of diosmin in the treatment of venous insufficiency and hemorrhoidal disease remains important. Diosmin itself has also evolved, being micronized for better biological availability and showing significant effects on the vascular system according to research.
News Cardiovascular Interventions with Continued Therapy with Dabigatran − Insights from the GLORIA-AF Study
An analysis using data from an international registry of patients with newly diagnosed atrial fibrillation evaluated the safety and efficacy of continued therapy with dabigatran during cardioversion or atrial fibrillation ablation, pacemaker implantation, and coronary angiography with possible stent implantation.
News Perioperative Management of Bleeding in Patients with von Willebrand Disease Using Coagulation Factors
Von Willebrand disease is one of the most common congenital bleeding disorders. It is a heterogeneous group of diseases with varying severity of clinical manifestations. Some patients require pharmacological prevention or treatment of bleeding as part of perioperative care. The administration of concentrates containing coagulation factors is currently the gold standard for certain types of von Willebrand disease.
News What Next for Patients with CLL After Stopping Venetoclax?
Standard care for untreated patients with chronic lymphocytic leukemia (CLL) is therapy based on venetoclax. However, managing further treatment when venetoclax needs to be discontinued remains a relatively unexplored area without standardized protocols.
News Comparison of Pharmacological Properties of Micronized Diosmin and Hesperidin in the Treatment of Chronic Venous Insufficiency and Hemorrhoids
Diosmin and hesperidin belong to the group of bioflavonoids, which currently find wide application in the treatment of chronic venous insufficiency and hemorrhoidal disease. Both flavonoids have been described to have a similar, but still not fully understood mechanism of action. Nevertheless, diosmin significantly differs from hesperidin, especially in pharmacokinetic parameters, which makes it the main carrier of the effect of venotonics.
News What Results Does Bimekizumab Achieve in Patients with PsA After 3 Years of Treatment?
Fresh findings from the BE ACTIVE study were published this year in the journal Rheumatology, which evaluated the effects of long-term treatment of individuals with psoriatic arthritis (PsA) with bimekizumab in terms of patient-reported outcomes (PROs).
News The Importance of Adequate Protein Intake in Critical Patients – Analysis of Data from an International Study
Adequate protein intake is a necessary part of care for critically ill patients and mitigates catabolic reactions associated with severe illness or injury. The benefits of proper determination and adherence to protein intake, however, have not been sufficiently assessed in detail. Therefore, this topic was the focus of a work analyzing data from an international observational multicenter study published in the Journal of Parenteral and Enteral Nutrition.
News Testing RAS Gene Mutations in Patients with Colorectal Cancer
Correct identification of the RAS oncogene variant is crucial for deciding the treatment of patients with colorectal cancer. Information on the prevalence of individual RAS gene mutations varies significantly in the literature, which may be due to different testing methods. The authors of the presented analysis focused on how the approach to testing RAS variants has evolved over time in Europe.
News Dupilumab Improves Skin and Systemic Symptoms of Atopic Dermatitis
A clinical study conducted in the USA and Canada demonstrated the efficacy of dupilumab in treating moderate to severe atopic dermatitis, improving both skin symptoms and suppressing systemic inflammatory markers.
News Efficacy of Baricitinib in Long-term Therapy of Rheumatoid Arthritis
Baricitinib selectively and reversibly inhibits Janus kinases JAK1 and JAK2 and is used in the treatment of adults with active rheumatoid arthritis (RA). Its safety during long-term administration has already been demonstrated by previous analyses, with treatment durations of up to 7 years. Equally important is the long-term efficacy of this drug, which was the focus of work presented in June of this year at the annual European rheumatology congress EULAR 2020.
News Safety Analysis of Baricitinib in Long-Term Treatment of Rheumatoid Arthritis
Janus kinase inhibitors are relatively new and very promising drugs, but their novelty also raises the question: Are they really safe? A brand-new analysis provides the answer by examining a cohort of patients treated for the longest duration to date.
News Retention – An Overlooked Parameter of Incontinence Products
In the Czech Republic and other European countries, the main criterion when choosing an incontinence product, apart from its size, is primarily absorption. This defines the amount of fluid the product can hold in its absorbent core, but it does not tell anything about its retention capability. What is retention and why is it important to know?
News Intravenous Thrombolysis in Ischemic Stroke Patients on Dabigatran Treatment
What are the outcomes of performing intravenous thrombolysis in patients with acute ischemic stroke after reversing the anticoagulant effect of dabigatran with idarucizumab? The answer is provided by a data analysis from real-world clinical practice in stroke centers, published by Czech authors.
News Is it possible to extend the life of diabetics thanks to modern treatment?
People aged 60 with type 2 diabetes are estimated to live on average 6-7 years less compared to their peers without a diabetes diagnosis. However, clinical study results suggest that modern therapy can prevent these lost years.
News Overlap of SGLT2 Inhibitors from Diabetology to Cardiology
As recent research shows, one of the modern groups of antidiabetic drugs - SGLT2 inhibitors, also known as gliflozins - brings benefits not only in diabetology but also in cardiology and nephrology. It has been confirmed that representatives of this class of drugs prolong patients' lives, reduce the incidence of major cardiovascular (CV) events and the risk of heart failure (HF), and improve renal function. A recently published study additionally indicates that the CV benefit of empagliflozin is independent of the number of compensated CV risk factors and manifests within the first 3 months of treatment.
News Cell-Based Implant as a Stable System for Biological Therapy Delivery
A team of scientists from Washington University in St. Louis focused on the possibility of delivering biological inhibitors for the treatment of rheumatoid arthritis using modified induced pluripotent stem cells. To verify the effectiveness of the therapy, they used a mouse model of rheumatoid arthritis, and their results represent progress in the development of rheumatoid arthritis treatment.
News View on the Treatment of Rheumatoid Arthritis with Baricitinib Using the NNT Indicator
Clinical parameters assessed by patients themselves are an important tool in evaluating the effectiveness of new drugs and are particularly significant in the evaluation of treatments for chronic painful conditions, such as rheumatoid arthritis (RA). An analysis of clinical trial results presented at the European Rheumatology e-Congress in June 2020 focused on the effectiveness of the Janus kinase inhibitor baricitinib on parameters assessed directly by patients. Effectiveness was analyzed using the NNT indicator.
News Meta-analysis of Efficacy and Safety of Third-Generation Antiseizure Medications in Adjunctive Treatment of Focal Seizures in Adults with Epilepsy
Epilepsy treatment is primarily symptomatic, aimed at reducing seizure frequency. However, more than 50% of patients do not achieve seizure freedom with monotherapy. Below we summarize the results of a meta-analysis comparing the efficacy and safety of third-generation antiseizure medications in the treatment of focal seizures in adults with epilepsy.
News Does Peritoneal Dialysis Have Its Place Even in Acute Cases?
In patients who urgently need to replace kidney function, hemodialysis traditionally played the role of the gold standard. Can peritoneal dialysis fully replace it?
News Brigatinib in Patients with ALK+ NSCLC – Final Results of the J-ALTA Clinical Study
At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early June 2022, the final results of the J-ALTA clinical study were presented. So how did brigatinib perform in the treatment of patients with ALK-positive NSCLC who were refractory to alectinib?